Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success.
First pivotal study win for Merck & Co.'s antibacterial antibody suggests that biologics could at last bring precision medicine to the anti-infective space.
This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially.
Husseini Manji, the Global Therapeutic Area Head of Neuroscience at Janssen, discusses the promise of NMDA receptor antagonists, anti-inflammatories and endocannabinoid modulators in psychiatry.
Digital prescription pills, set to hit the market soon, offer the opportunity to address key drug adherence challenges in clinical practice and clinical trials.